In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12477
Abstract: Polo‐like kinase 1 (Plk1), a master regulator of mitosis and the DNA damage response, is considered to be an intriguing target in the research field of mitotic intervention. The observation that Plk1 is overexpressed in… read more here.
Keywords: plk1; like kinase; volasertib; polo like ... See more keywords
THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.87_2629
Abstract: to investigate the signaling pathways altered upon drug treatment. An orthotoppic PDX model was established from a MCL patient with dual resistance to ibrutinib-venetoclax. Single agent copanlisib at 6 mg/kg/2d, idelalisib at 50 mg/kg/2d, ibrutinib… read more here.
Keywords: volasertib; ibrutinib venetoclax; copanlisib; resistance ... See more keywords